Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

Trastuzumab has been shown to improve the survival outcomes of HER2 positive breast cancer patients. However, a significant proportion of HER2-positive patients are either inherently resistant or develop resistance to trastuzumab. We assessed the effects of neratinib, an irreversible panHER inhibito...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Canonici, Alexandra, Gijsen, Merel, Mullooly, Maeve, Bennett, Ruth, Bouguern, Noujoude, Pedersen, Kasper, O'Brien, Neil A, Roxanis, Ioannis, Li, Ji-Liang, Bridge, Esther, Finn, Richard, Slamon, Dennis, McGowan, Patricia, Duffy, Michael J., O'Donovan, Norma, Crown, John, Kong, Anthony
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2013
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3858548/
https://ncbi.nlm.nih.gov/pubmed/24009064
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы